Our glaucoma-specific PROMs provide comprehensive and valid measurement of the
quality of life impact of glaucoma, associated vision impairment and glaucoma treatments.
GlauCAT™️
GlauCAT™️ is a suite of computerised adaptive tests (CATs) that measure the impact of glaucoma on 12 domains of quality of life.
Visual symptoms
Ocular comfort symptoms
Activity limitation
Mobility
Emotional
Concerns
Social
Convenience (general)
Convenience (treatment)
Economic
Driving
Lighting
GlauCAT™️ - Asian
GlauCAT™️ – Asian is a suite of computerised adaptive tests (CATs) that measure the impact of glaucoma on 7 domains of quality of life.
Ocular comfort symptoms
Activity limitation
Lighting
Mobility
Socio-emotional
Concerns
Glaucoma management
The GlauCAT™️ instruments comprise hundreds of items in calibrated item banks. Using CAT (a type of artificial intelligence) the GlauCAT™️ systems iteratively select items that most closely match the person’s quality of life at that point in the test. This “smart-technology” means that patients answer only a small number of items and scores are generated in ~2 minutes per domain.
With a user-friendly interface and automated feedback system, the GlauCAT™️ systems offer researchers, clinicians and clinical trial teams a precise, efficient and culturally applicable PROM to evaluate the effectiveness of treatment therapies, including topical medications, laser, and surgery, from the patient’s perspective.
Publications
GlauCAT™️ domain and item development and refinement
GlauCAT™️ - Asian domain and item development and refinement
Utilisation
Psychometric testing of GlauCAT™️ item banks using data from 293 patients with glaucoma.
The GlauCAT™️ item banks were used in the Glaucoma Initial Treatment Study to compare this impact of topical medication and selective laser trabeculoplasty as initial glaucoma treatment.
GlauCAT™️ is currently being used in a clinical trial in patients with glaucoma to measure the impact of Minimally Invasive Glaucoma Surgery (MIGS) on quality of life at the Singapore National Eye Centre.
GlauCAT™️ is currently being used in an observational investigation by Perfuse Therapeutics of patients with open angle glaucoma and progressive visual field loss to understand the natural history of the condition and its impact on quality of life.
GlauCAT™️ has also been implemented into glaucoma clinics at Mass. Eye and Ear Hospital, with patients’ GlauCAT™️ scores being incorporated into clinical care and shared-decision making with patients during consultations with their treating ophthalmologist.
Researchers at the Wilmer Eye Institute are currently assessing patient experience with the GlauCAT™️ test administration process to determine the most practical way to employ the test and to what extent testing needs to be customised, as well as exploring what QoL domains are most affected in glaucoma patients across the severity of the condition.
Glaucoma Utility instrument (Glau-U)
Glau-U is a preference-based utility instrument that can differentiate between
glaucoma severity and vision impairment levels.
Patients rate their difficulty on six aspects of glaucoma-specific QoL and scores
are converted to utilities using utility weights.
Activities of daily living
Lighting and glare
Movement
Eye discomfort
Other effects of glaucoma and its treatment
Social and emotional effects of glaucoma
Glau-U enables researchers to measure health utilities associated with glaucoma and changes following treatment interventions.
Being situated on the quality-adjusted life year (QALY) scale, Glau-U is suitable for cost-effectiveness studies relating to glaucoma treatments, informing health policies related to personnel, resources and funding allocated to end stage glaucoma, eye care and rehabilitation.
